Table 2.

Average Changes in Strength, Density, and Mass by Treatment Group: Year 2 Changes Compared With Baseline

Variable	PTH-PLB (N = 38)	PTH-ALN (N = 45)	CMB-ALN (N = 39)	ALN-ALN (N = 40)	Between-treatment p value
Femoral strength	1.17 ± 3.53	7.74 ± 3.25	4.18 ± 3.49	4.83 ± 3.44	0.06
Trab CPMT strength	1.27 ± 2.57*	6.84 ± 2.36†‡	2.85 ± 2.54§	4.07 ± 2.51	<0.05
Periph CPMT strength	−0.90 ± 1.83	1.65 ± 1.67	1.00 ± 1.80	1.63 ± 1.78	0.16
Geometric strength	0.45 ± 1.39*	0.47 ± 1.27*	0.70 ± 1.37*	2.76 ± 1.35†	<0.05
Areal BMD (total hip, DXA)	−0.17 ± 1.44*	4.79 ± 1.32†	3.29 ± 1.42†	3.12 ± 1.40†	<0.0001
Integral density	−0.79 ± 1.53*	3.11 ± 1.41†	2.03 ± 1.51†	1.57 ± 1.50†	<0.01
Integral mass	−0.87 ± 1.89*	2.72 ± 1.74†	2.13 ± 1.86†	2.55 ± 1.84†	<0.05
Trab density	−0.47 ± 1.46*	3.38 ± 1.35†	2.40 ± 1.45†	1.79 ± 1.43†	<0.01
Trab mass	−0.47 ± 1.76*	2.96 ± 1.62†	2.59 ± 1.74†	2.79 ± 1.72†	<0.05
Cort density	0.16 ± 0.61	−0.17 ± 0.56	0.35 ± 0.60	0.33 ± 0.59	0.56
Cort mass	−2.46 ± 5.47	0.78 ± 5.03	−0.66 ± 5.40	1.34 ± 5.33	0.76
Trab CPMT density	0.95 ± 2.22*	6.49 ± 2.04†‡	4.21 ± 2.19†	3.14 ± 2.16§	<0.01
Trab CPMT mass	1.04 ± 2.61*	6.00 ± 2.40†	4.52 ± 2.57†	4.54 ± 2.54	<0.05
Periph CPMT density	−1.84 ± 1.56	0.65 ± 1.44	0.53 ± 1.55	0.67 ± 1.52	0.06
Periph CPMT mass	−2.14 ± 1.92	0.42 ± 1.76	0.46 ± 1.89	1.10 ± 1.87	0.09

See Table 1 for legends.

For between-treatment effects (by ANOVA), * ≠ ^† and ^‡ ≠ ^§denote significant posthoc differences in changes between treatments (p < 0.05 at least).